181 results about "Aerosol composition" patented technology

Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.

A pressure resistant plastic bottle for containing and dispensing an aerosol composition. The plastic bottle is comprised of a hollow elongate body having a central portion, a top portion and an opposite bottom portion with the central portion having an inwardly concave configuration extending along its longitudinal direction. The bottom portion of the elongate body is integral with the central portion and defines an outwardly projecting convexly shaped configuration. The top portion of the bottle is integral with the central portion and has an outwardly convex configuration extending along its longitudinal direction and defines a neck having an opening for receiving and dispensing the aerosol composition. A closure covers the opening and is sealingly attached to the neck to contain the aerosol within the plastic bottle.

The present invention provides a pharmaceutical composition for transdermal delivery comprising: one or more physiologically active agents; one or more dermal penetration enhancers; a pharmaceutically acceptable carrier comprising a volatile solvent; and a hydrofluorocarbon propellent; wherein the carrier and penetration enhancers combine to provide a single-phase solution of the one or more physiologically active agents.

A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.

The present invention provides stable aerosol cream mousse composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick, rich, creamy, mousse-type rheology with excellent spreading, perception of spreading, and feel. The aerosol composition is based on the combination of component (A) a cationic surfactant, which is generally a quaternary ammonium compound such as e.g., ditallow dimethyl ammonium chloride; (B) a fatty alcohol, such as cetyl and stearyl alcohol; and (C) carbon dioxide.

This invention relates to a “high lower alcohol content” (>40% v/v of a C_1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise a C_1-4 alcohol, (>40% v/v), a silicone-based surfactant of at least 0.001% by weight for foaming to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and mosturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

The present invention pertains to aerosols which comprise a first compound which is physiologically active and a second compound which is different from the first compound. Such aerosols may be produced “on demand” and can be used to control drug release, to improve vaporizability, or to reduce, modify or eliminate undesirable taste associated with a drug aerosol. The present invention also pertains to methods for producing such aerosols.

Spray compositions and particularly anhydrous aerosol compositions containing particulate antiperspirant actives exhibit a tendency for nozzle blockage, impeding discharge of the contents when a polyol humectant, such as glycerol, is blended into its base composition. The problem is overcome or at least ameliorated by preparation of a base composition, suitable for employment in conjunction with a propellant, that contains a low molecular weight (liquid) polyethylene glycol (PEG) as humectant, and particularly a PEG of molecular weight 150 to 500.

Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.

Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.

Non-foaming aqueous emulsion compositions; methylparaben-based preservative systems for aqueous aerosol compositions having a pH at or above a pH where methylparaben begins to hydrolyze; cosmetic, household, and human and veterinary pharmaceutical products containing these compositions.

Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

An aerosol paint composition includes an alkyd resin; one or more solvents; an organoclay; an anti-settling wax; a dispersing agent; one or more pigments; a drying agent; an anti-skinning agent; a fragrance; and a fungicide.

Disclosed is an aerosol composition that includes water, an organic propellant, molasses components, and a surfactant. The composition preferably further includes an anti-agglomeration agent to inhibit agglomeration of insoluble materials and a sugar stabilizer to inhibit crystallization of sugar in the composition. Also disclosed are methods for feeding an animal by dispensing an aqueous solution of a sugar from an aerosol device, preferably an aerosol device that includes an aerosol composition as described above.

Described herein are emulsions and compositions for the treatment of acne vulgaris. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise clindamycin phosphate and a buffer salt, and may exhibit decreased rates of clindamycin phosphate hydrolysis. Also described are methods of treating acne vulgaris, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.